Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9
Abstract The association between pulmonary sequelae and markers of disease severity, as well as pro-fibrotic mediators, were studied in 108 patients 3 months after hospital admission for COVID-19. The COPD assessment test (CAT-score), spirometry, diffusion capacity of the lungs (DLCO), and chest-CT...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/88393d531e5a4b23b4265b267e8189ee |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:88393d531e5a4b23b4265b267e8189ee |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:88393d531e5a4b23b4265b267e8189ee2021-12-05T12:12:38ZPersistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-910.1038/s41598-021-02547-x2045-2322https://doaj.org/article/88393d531e5a4b23b4265b267e8189ee2021-12-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-02547-xhttps://doaj.org/toc/2045-2322Abstract The association between pulmonary sequelae and markers of disease severity, as well as pro-fibrotic mediators, were studied in 108 patients 3 months after hospital admission for COVID-19. The COPD assessment test (CAT-score), spirometry, diffusion capacity of the lungs (DLCO), and chest-CT were performed at 23 Norwegian hospitals included in the NOR-SOLIDARITY trial, an open-labelled, randomised clinical trial, investigating the efficacy of remdesivir and hydroxychloroquine (HCQ). Thirty-eight percent had a CAT-score ≥ 10. DLCO was below the lower limit of normal in 29.6%. Ground-glass opacities were present in 39.8% on chest-CT, parenchymal bands were found in 41.7%. At admission, low pO2/FiO2 ratio, ICU treatment, high viral load, and low antibody levels, were predictors of a poorer pulmonary outcome after 3 months. High levels of matrix metalloproteinase (MMP)-9 during hospitalisation and at 3 months were associated with persistent CT-findings. Except for a negative effect of remdesivir on CAT-score, we found no effect of remdesivir or HCQ on long-term pulmonary outcomes. Three months after hospital admission for COVID-19, a high prevalence of respiratory symptoms, reduced DLCO, and persistent CT-findings was observed. Low pO2/FiO2 ratio, ICU-admission, high viral load, low antibody levels, and high levels of MMP-9 were associated with a worse pulmonary outcome.Tøri Vigeland LerumNiklas Nyboe MaltzahnPål AukrustMarius TrøseidKaterina Nezvalova HenriksenTrine KåsineAnne-Ma Dyrhol-RiiseBirgitte StiksrudMette HaugliBjørn BlombergBård Reiakvam KittangAsgeir JohannessenRaisa HannulaSaad AballiAnders Benjamin KildalRagnhild EikenTuva Børresdatter DahlFridtjof Lund-JohansenFredrik MüllerJezabel Rivero RodriguezCarin MeltzerGunnar EinvikThor UelandInge Christoffer OlsenNOR-SOLIDARITY ConsortiumAndreas Barratt-DueTrond Mogens AaløkkenOle Henning SkjønsbergNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Tøri Vigeland Lerum Niklas Nyboe Maltzahn Pål Aukrust Marius Trøseid Katerina Nezvalova Henriksen Trine Kåsine Anne-Ma Dyrhol-Riise Birgitte Stiksrud Mette Haugli Bjørn Blomberg Bård Reiakvam Kittang Asgeir Johannessen Raisa Hannula Saad Aballi Anders Benjamin Kildal Ragnhild Eiken Tuva Børresdatter Dahl Fridtjof Lund-Johansen Fredrik Müller Jezabel Rivero Rodriguez Carin Meltzer Gunnar Einvik Thor Ueland Inge Christoffer Olsen NOR-SOLIDARITY Consortium Andreas Barratt-Due Trond Mogens Aaløkken Ole Henning Skjønsberg Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9 |
| description |
Abstract The association between pulmonary sequelae and markers of disease severity, as well as pro-fibrotic mediators, were studied in 108 patients 3 months after hospital admission for COVID-19. The COPD assessment test (CAT-score), spirometry, diffusion capacity of the lungs (DLCO), and chest-CT were performed at 23 Norwegian hospitals included in the NOR-SOLIDARITY trial, an open-labelled, randomised clinical trial, investigating the efficacy of remdesivir and hydroxychloroquine (HCQ). Thirty-eight percent had a CAT-score ≥ 10. DLCO was below the lower limit of normal in 29.6%. Ground-glass opacities were present in 39.8% on chest-CT, parenchymal bands were found in 41.7%. At admission, low pO2/FiO2 ratio, ICU treatment, high viral load, and low antibody levels, were predictors of a poorer pulmonary outcome after 3 months. High levels of matrix metalloproteinase (MMP)-9 during hospitalisation and at 3 months were associated with persistent CT-findings. Except for a negative effect of remdesivir on CAT-score, we found no effect of remdesivir or HCQ on long-term pulmonary outcomes. Three months after hospital admission for COVID-19, a high prevalence of respiratory symptoms, reduced DLCO, and persistent CT-findings was observed. Low pO2/FiO2 ratio, ICU-admission, high viral load, low antibody levels, and high levels of MMP-9 were associated with a worse pulmonary outcome. |
| format |
article |
| author |
Tøri Vigeland Lerum Niklas Nyboe Maltzahn Pål Aukrust Marius Trøseid Katerina Nezvalova Henriksen Trine Kåsine Anne-Ma Dyrhol-Riise Birgitte Stiksrud Mette Haugli Bjørn Blomberg Bård Reiakvam Kittang Asgeir Johannessen Raisa Hannula Saad Aballi Anders Benjamin Kildal Ragnhild Eiken Tuva Børresdatter Dahl Fridtjof Lund-Johansen Fredrik Müller Jezabel Rivero Rodriguez Carin Meltzer Gunnar Einvik Thor Ueland Inge Christoffer Olsen NOR-SOLIDARITY Consortium Andreas Barratt-Due Trond Mogens Aaløkken Ole Henning Skjønsberg |
| author_facet |
Tøri Vigeland Lerum Niklas Nyboe Maltzahn Pål Aukrust Marius Trøseid Katerina Nezvalova Henriksen Trine Kåsine Anne-Ma Dyrhol-Riise Birgitte Stiksrud Mette Haugli Bjørn Blomberg Bård Reiakvam Kittang Asgeir Johannessen Raisa Hannula Saad Aballi Anders Benjamin Kildal Ragnhild Eiken Tuva Børresdatter Dahl Fridtjof Lund-Johansen Fredrik Müller Jezabel Rivero Rodriguez Carin Meltzer Gunnar Einvik Thor Ueland Inge Christoffer Olsen NOR-SOLIDARITY Consortium Andreas Barratt-Due Trond Mogens Aaløkken Ole Henning Skjønsberg |
| author_sort |
Tøri Vigeland Lerum |
| title |
Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9 |
| title_short |
Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9 |
| title_full |
Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9 |
| title_fullStr |
Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9 |
| title_full_unstemmed |
Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9 |
| title_sort |
persistent pulmonary pathology after covid-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9 |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/88393d531e5a4b23b4265b267e8189ee |
| work_keys_str_mv |
AT tørivigelandlerum persistentpulmonarypathologyaftercovid19isassociatedwithhighviralloadweakantibodyresponseandhighlevelsofmatrixmetalloproteinase9 AT niklasnyboemaltzahn persistentpulmonarypathologyaftercovid19isassociatedwithhighviralloadweakantibodyresponseandhighlevelsofmatrixmetalloproteinase9 AT palaukrust persistentpulmonarypathologyaftercovid19isassociatedwithhighviralloadweakantibodyresponseandhighlevelsofmatrixmetalloproteinase9 AT mariustrøseid persistentpulmonarypathologyaftercovid19isassociatedwithhighviralloadweakantibodyresponseandhighlevelsofmatrixmetalloproteinase9 AT katerinanezvalovahenriksen persistentpulmonarypathologyaftercovid19isassociatedwithhighviralloadweakantibodyresponseandhighlevelsofmatrixmetalloproteinase9 AT trinekasine persistentpulmonarypathologyaftercovid19isassociatedwithhighviralloadweakantibodyresponseandhighlevelsofmatrixmetalloproteinase9 AT annemadyrholriise persistentpulmonarypathologyaftercovid19isassociatedwithhighviralloadweakantibodyresponseandhighlevelsofmatrixmetalloproteinase9 AT birgittestiksrud persistentpulmonarypathologyaftercovid19isassociatedwithhighviralloadweakantibodyresponseandhighlevelsofmatrixmetalloproteinase9 AT mettehaugli persistentpulmonarypathologyaftercovid19isassociatedwithhighviralloadweakantibodyresponseandhighlevelsofmatrixmetalloproteinase9 AT bjørnblomberg persistentpulmonarypathologyaftercovid19isassociatedwithhighviralloadweakantibodyresponseandhighlevelsofmatrixmetalloproteinase9 AT bardreiakvamkittang persistentpulmonarypathologyaftercovid19isassociatedwithhighviralloadweakantibodyresponseandhighlevelsofmatrixmetalloproteinase9 AT asgeirjohannessen persistentpulmonarypathologyaftercovid19isassociatedwithhighviralloadweakantibodyresponseandhighlevelsofmatrixmetalloproteinase9 AT raisahannula persistentpulmonarypathologyaftercovid19isassociatedwithhighviralloadweakantibodyresponseandhighlevelsofmatrixmetalloproteinase9 AT saadaballi persistentpulmonarypathologyaftercovid19isassociatedwithhighviralloadweakantibodyresponseandhighlevelsofmatrixmetalloproteinase9 AT andersbenjaminkildal persistentpulmonarypathologyaftercovid19isassociatedwithhighviralloadweakantibodyresponseandhighlevelsofmatrixmetalloproteinase9 AT ragnhildeiken persistentpulmonarypathologyaftercovid19isassociatedwithhighviralloadweakantibodyresponseandhighlevelsofmatrixmetalloproteinase9 AT tuvabørresdatterdahl persistentpulmonarypathologyaftercovid19isassociatedwithhighviralloadweakantibodyresponseandhighlevelsofmatrixmetalloproteinase9 AT fridtjoflundjohansen persistentpulmonarypathologyaftercovid19isassociatedwithhighviralloadweakantibodyresponseandhighlevelsofmatrixmetalloproteinase9 AT fredrikmuller persistentpulmonarypathologyaftercovid19isassociatedwithhighviralloadweakantibodyresponseandhighlevelsofmatrixmetalloproteinase9 AT jezabelriverorodriguez persistentpulmonarypathologyaftercovid19isassociatedwithhighviralloadweakantibodyresponseandhighlevelsofmatrixmetalloproteinase9 AT carinmeltzer persistentpulmonarypathologyaftercovid19isassociatedwithhighviralloadweakantibodyresponseandhighlevelsofmatrixmetalloproteinase9 AT gunnareinvik persistentpulmonarypathologyaftercovid19isassociatedwithhighviralloadweakantibodyresponseandhighlevelsofmatrixmetalloproteinase9 AT thorueland persistentpulmonarypathologyaftercovid19isassociatedwithhighviralloadweakantibodyresponseandhighlevelsofmatrixmetalloproteinase9 AT ingechristofferolsen persistentpulmonarypathologyaftercovid19isassociatedwithhighviralloadweakantibodyresponseandhighlevelsofmatrixmetalloproteinase9 AT norsolidarityconsortium persistentpulmonarypathologyaftercovid19isassociatedwithhighviralloadweakantibodyresponseandhighlevelsofmatrixmetalloproteinase9 AT andreasbarrattdue persistentpulmonarypathologyaftercovid19isassociatedwithhighviralloadweakantibodyresponseandhighlevelsofmatrixmetalloproteinase9 AT trondmogensaaløkken persistentpulmonarypathologyaftercovid19isassociatedwithhighviralloadweakantibodyresponseandhighlevelsofmatrixmetalloproteinase9 AT olehenningskjønsberg persistentpulmonarypathologyaftercovid19isassociatedwithhighviralloadweakantibodyresponseandhighlevelsofmatrixmetalloproteinase9 |
| _version_ |
1718372142096056320 |